8,536 research outputs found
Seminal plasma promotes lesion development in a xenograft model of endometriosis
No full textAbstract not availableJonathan T. McGuane, Katherine M. Watson, Jamie Zhang, M. Zahied Johan, Zhao Wang, Gabriel Kuo, David J. Sharkey, Sarah A. Robertson, and M. Louise Hul
Data structures and algorithms in C++ / Michael T. Goodrich, Roberto Tamassia, David M. Mount.
No full textIncludes bibliographical references and index.Includes bibliographical references and index.xxii, 714 pages :"An updated, innovative approach to data structures and algorithms Written by an author team of experts in their fields, this authoritative guide demystifies even the most difficult mathematical concepts so that you can gain a clear understanding of data structures and algorithms in C++. The unparalleled author team incorporates the object-oriented design paradigm using C++ as the implementation language, while also providing intuition and analysis of fundamental algorithms. Offers a unique multimedia format for learning the fundamentals of data structures and algorithms Allows you to visualize key analytic concepts, learn about the most recent insights in the field, and do data structure design Provides clear approaches for developing programs Features a clear, easy-to-understand writing style that breaks down even the most difficult mathematical concepts Building on the success of the first edition, this new version offers you an innovative approach to fundamental data structures and algorithms."-
A Natural History of Botanical Therapeutics
No full textPlants have been used as a source of medicine throughout history and continue to serve as the basis for many pharmaceuticals used today. Although the modern pharmaceutical industry was born from botanical medicine, synthetic approaches to drug discovery have become standard. However, this modern approach has led to a decline in new drug development in recent years and a growing market for botanical therapeutics that are currently available as dietary supplements, drugs, or botanical drugs. Most botanical therapeutics are derived from medicinal plants that have been cultivated for increased yields of bioactive components. The phytochemical composition of many plants has changed over time, with domestication of agricultural crops resulting in the enhanced content of some bioactive compounds and diminished content of others. Plants continue to serve as a valuable source of therapeutic compounds because of their vast biosynthetic capacity. A primary advantage of botanicals is their complex composition consisting of collections of related compounds having multiple activities that interact for a greater total activity.Research supported by NIH Grant P50 AT002776-01 from the National Center for Complementary and Alternative Medicine (NCCAM) and Office of Dietary Supplements (ODS) which funds the Botanical Research Center; also supported by Fogarty International Center of the National Institutes of Health under U01 TW006674 for the International Cooperative Biodiversity Groups; and Rutgers University.NIH P50 AT002776-01; by William CefaluNIH U01 TW006674The published version of this article is available at: http://www.metabolismjournal.com
Botanicals as epigenetic modulators for mechanisms contributing to development of metabolic syndrome
No full textEpigenetics refers to heritable changes in gene expression that are not attributable to changes in DNA sequence and impacts many areas of applied and basic biology including developmental biology, gene therapy, somatic cell nuclear transfer, somatic cell reprogramming, and stem cell biology. Epigenetic changes are known to contribute to aging in addition to multiple disease states. Epigenetic changes can be influenced by environmental factors that in turn can be inherited by daughter cells during cell division and can also be inherited through the germ line. Thus, it is intriguing to consider that epigenetics, in general, may play a role in human conditions that are strongly influenced by changes in the environment and lifestyle. In particular, metabolic syndrome, a condition increasing in prevalence around the world, is one such condition for which epigenetics is postulated to contribute. Epigenetic defects (epimutations) are thought to be more easily reversible (when compared with genetic defects) and, as such, have inspired efforts to identify novel compounds that correct epimutations or preventprogression to the disease state. These efforts have resulted in the development of a rapidly growing new field being referred to as epigenetic therapy. To date, 2 classes of drugs have received the most attention, that is, DNA methyltransferase inhibitors and histone deacetylase inhibitors; but recent data suggest that botanical sources may be a rich source of agents that can potentially modulate the epigenome and related pathways and potentially be useful in attenuating the progression of many factors related to development of metabolic syndrome. This review will provide an overview of the field of epigenetics, epigenetic therapy, and the molecules currently receiving the most interest with respect to treatment, and review data on botanical compounds that show promise in this regard.This work was supported in part by NIH Grant P50AT002776-01 from the National Center for Complementary and Alternative Medicine (NCCAM) and the Office of Dietary Supplements (ODS).NIH P50 AT002776-01; by William CefaluThe published version of this article is available at: http://www.metabolismjournal.com
Measurement of the top-quark mass in all-jets events in pp collisions at = 7 TeV
Full text linkThe mass of the top quark is measured using a sample of candidate events with at least six jets in the final state. The sample is selected from data collected with the CMS detector in pp collisions at = 7 TeV in 2011 and corresponds to an integrated luminosity of 3.54 . The mass is reconstructed for each event employing a kinematic fit of the jets to a hypothesis. The top-quark mass is measured to be 173.49 0.69(stat.) 1.21(syst.) GeV. A combination with previously published measurements in other decay modes by CMS yields a mass of 173.54 0.33(stat.) 0.96(syst.) GeV
Bioactives of Artemisia dracunculus L enhance cellular insulin signaling in primary human skeletal muscle culture
No full textAn alcoholic extract of Artemisia dracunculus L (PMI 5011) has been shown to decrease glucose and improve insulin levels in animal models, suggesting an ability to enhance insulin sensitivity. We sought to assess the cellular mechanism by which this botanical affects carbohydrate metabolism in primary human skeletal muscle culture. We measured basal and insulin-stimulated glucose uptake, glycogen accumulation, hosphoinositide 3 (PI-3) kinase activity, and Akt phosphorylation in primary skeletal muscle culture from subjects with type 2 diabetes mellitus incubated with or without various concentrations of PMI 5011. We also analyzed the abundance of insulin receptor signaling proteins, for example, IRS-1, IRS-2, and PI-3 kinase. Glucose uptake was significantly increased in the presence of increasing concentrations of PMI 5011. In addition, glycogen accumulation, observed to be decreased with increasing free fatty acid levels, was partially restored with PMI 5011. PMI 5011 treatment did not appear to significantly affect protein abundance for IRS-1, IRS-2, PI-3 kinase, Akt, insulin receptor, or Glut-4. However, PMI 5011 significantly decreased levels of a specific protein tyrosine phosphatase, that is, PTP1B. Time course studies confirmed that protein abundance of PTP1B decreases in the presence of PMI 5011. The cellular mechanism of action to explain the effects by which an alcoholic extract of A dracunculus L improves carbohydrate metabolism on a clinical level may be secondary to enhancing insulin receptor signaling and modulating levels of a specific protein tyrosine phosphatase, that is, PTP1B.Supported by NIH Grant P50AT002776-01 from the National Center for Complementary and Alternative Medicine (NCCAM) and the Office of Dietary Supplements (ODS), which funds the Botanical Research Center of Pennington Biomedical Research Center and The Biotech Center of Rutgers University.NIH P50 AT002776-01; by William CefaluThe published version of this article is available at: http://www.metabolismjournal.com
Exploiting knowledge of immune selection in HIV-1 to detect HIV-specific CD8 T-cell responses
Full text linkSince HLA-restricted cytotoxic T-cell responses select specific polymorphisms in HIV-1 sequences and HLA diversity is relatively static in human populations, we investigated the use of peptide epitopes based on sites of HLA-associated adaptation in HIV-1 sequences to stimulate and detect T-cell responses ex vivo. These "HLA-optimised" peptides captured more HIV-1 Nef-specific responses compared with overlapping peptides of a single consensus sequence, in interferon-γ enzyme linked immunospot assays. Sites of immune selection can reveal more immunogenic epitopes in HLA-diverse populations and offer insights into the nature of HLA-epitope targeting, which could be applied in vaccine design
- …
